GlobeNewswire by notified

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

Share

Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s 2023 full-year financial results on Thursday, March 28, 2024.

Inventiva’s 2023 full-year financial results will be published on Wednesday, March 27, 2024 at 4:00 pm (New York), 9:00 pm (Paris).

Frédéric Cren, Chairman, CEO and cofounder of Inventiva, Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, and Jean Volatier, Chief Financial Officer of Inventiva, will hold a conference call in English, followed by a Q&A session, on Thursday, March 28, 2024, at8:00 am (New York), 1:00 pm (Paris).

The conference call and the slides of the presentation will be webcast live at: https://edge.media-server.com/mmc/p/eh78kegs and also available on Inventiva’s website in the “Investors – Financial results” section.

In order to receive the conference access information necessary to join the conference call, it is required to register in advance using the following link: https://register.vevent.com/register/BIca56dabf4edf46ecaaca0e735626f044. Participants will need to use the conference access information provided in the e-mail received at the point of registering (dial-in number and access code).

A replay of the conference call and the presentation will be available after the event at: http://inventivapharma.com/investors/financial-results-presentations/.



About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH/NASH, and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate, has a pipeline of two preclinical programs and continues to explore other development opportunities to add to its pipeline.

Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with MASH/NASH, a common and progressive chronic liver disease for which there are currently no approved therapies.

Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is also in the process of selecting a candidate for its Hippo signaling pathway program.

The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com

Contacts

Inventiva

Pascaline Clerc
EVP, Strategy and Corporate Affairs
media@inventivapharma.com
   +1 202 499 8937
Brunswick Group
Tristan Roquet Montegon /
Aude Lepreux /
Julia Cailleteau
Media relations
inventiva@brunswickgroup.com

   +33 1 53 96 83 83
Westwicke, an ICR Company
Patricia L. Bank
Investor relations
patti.bank@westwicke.com

         +1 415 513-1284

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Ekstraordinære indfrielser (CK 93)21.5.2024 09:20:02 CEST | pressemeddelelse

I medfør af kapitalmarkedsloven § 24, oplyser DLR Kredit hermed om ekstraordinære indfrielser pr. fredag den 17. maj 2024. Oplysningerne fremgår af vedhæftede fil. Denne meddelelse er offentliggjort med henblik på opfyldelse af transparensdirektivets krav om offentliggørelse. Oplysningerne vil endvidere på sædvanlig måde blive formidlet via Nasdaq Copenhagen. Spørgsmål kan rettes til: Head of Rating & IR Jakob Kongsgaard Olsson tlf. nr. 33 42 07 06. Med venlig hilsen DLR Kredit A/S Vedhæftet fil ck93-2024-05-17

Photocat A/S and Nexler Sp. z.o.o. signing a groundbreaking 5-years partnership agreement and NOxOFF license agreement to revolutionize NOx reduction in the roofing industry.21.5.2024 09:20:00 CEST | Press release

May 21st 2024 Photocat A/S and Nexler Sp. z.o.o. signing a groundbreaking 5-years partnership agreement and NOxOFF license agreement to revolutionize NOx reduction in the roofing industry. The agreement will span over a minimum quantity of 1 million m2 produced. Roskilde, Denmark. May 21, 2024 – Photocat, is pleased to announce a strategic 5-years Partnership and License agreement with Nexler Sp. z.o.o., a prominent Polish based bitumen roofing company. This License agreement follows agreements made with IKO, Danosa, Katepal, and C. Hasse & Sohn to use IPR developed and owned by Photocat. Leveraging Photocat's extensive patent base, developed at the company's headquarters in Denmark, this collaboration represents a significant step forward in bringing cutting-edge air purification solutions to the roofing industry while ensuring the protection of intellectual property rights. With this License agreement, Photocat is further expanding its partnership network as well as its geographical

Prosafe SE: Operational Update - May 202421.5.2024 09:16:23 CEST | Press release

Oslo, 21 May 2024 Fleet utilisation for April 2024 was 56 percent. Safe Notos and Safe Eurus had utilisation of 100 percent in April 2024 while Safe Zephyrus had utilisation of 93 percent. Safe Concordia had utilisation of 100 percent in April 2024. Safe Caledonia is laid up at Scapa Flow in the UK pending future work. Safe Boreas and Safe Scandinavia are laid up in Norway pending future work. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to https://www.prosafe.com For further information, please contact: Terje Askvig, CEO Phone: +47 952 03 886 Reese McNeel, CFO Phone: +47 415 08 186 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Debtor distribution data (CK92) - Totalkredit A/S21.5.2024 09:15:00 CEST | Press release

To the Nasdaq Copenhagen Debtor distribution data (CK92) Pursuant to s 24 Danish Capital Markets Act, Totalkredit A/S hereby publishes debtor distribution data for callable mortgage bond series as at 17 May 2024 in the attached file. Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/filarkiv/. For further information about data format and contents, please refer to the Nasdaq website. Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21. Yours sincerely Totalkredit A/S Attachments Debtor distribution data - Totalkredit A_S - 17-05-2024debisamstk

Debitormassens sammensætning (CK92) - Nykredit Realkredit A/S21.5.2024 09:15:00 CEST | pressemeddelelse

Til Nasdaq Copenhagen Debitormassens sammensætning (CK92) I medfør af kapitalmarkedsloven § 24 offentliggør Nykredit Realkredit A/S hermed oplysninger om debitormassens sammensætning for konverterbare realkreditobligationer pr. den 17. maj 2024 i vedhæftede fil. Oplysningerne vil endvidere på sædvanlig måde blive formidlet via Nasdaq Copenhagen. Oplysningerne findes også i excel-format i Nykredits obligationsdatabase på https://www.nykredit.com/filarkiv/. For yderligere informationer om dataformat og -indhold henvises til Nasdaqs hjemmeside. Spørgsmål kan rettes til head of investor relations Morten Bækmand Nielsen på tlf. 44 55 15 21. Med venlig hilsen Nykredit Realkredit A/S Vedhæftede filer Debitormassens sammensætning - Nykredit Realkredit A_S - 17-05-2024debisams

HiddenA line styled icon from Orion Icon Library.Eye